Skywalker™ Joint Replacement Surgical Robot Completes First-in-Man Case in Human Trial

The Skywalker™ Joint Replacement Robot developed by MicroPort™ OrthoBot recently completed a robotic-assisted total knee arthroplasty, which is the first-in-man case in a human trial at the Shanghai Ninth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. The Suzhou, China-based company is a subsidiary of MicroPort™ MedBot. The case was successfully performed on a female patient by Director Huwui Li from the hospital’s orthopedic department. A post-operative X-ray check showed the best possible restoration of the limb alignment. The successful completion of the robotic-assisted total knee arthroplasty marked the first patient enrollment of the human trial of the Skywalker™ Joint Replacement Robot.

The Skywalker™ Joint Replacement Robot has been granted entry into the Special Review Procedure for Innovative Medical Devices (“Green Path”) of National Medical Products Administration of China (NMPA), which is expected to shorten its time to market in China and filled the void of Chinese companies in the field of joint replacement robots. When launched, the product will take advantage of its most cutting-edge therapeutic rationale and advanced tool to further improve the overall industry planning in the field of orthopedics for MicroPort®. The product will also combine the unique Medial-Pivot Knee of MicroPort® and strengthen the core advantages of MicroPort® including innovative designs and industry-leading manufacturing capability. In the end, MicroPort® will provide patients worldwide with more high-quality and accessible integrated solutions in the field of orthopedics.
MicroPort Scientific Corporation Announces Completion of Placing

MicroPort Scientific Corporation (the "Company", or "MicroPort"") (HKEX: 00853), a leading medical device group focusing on innovating, manufacturing and marketing high-end medical devices globally, announced on July 2 that it has completed the placing (the “Placing”) of 65,958,000 new shares (the “Placing Shares”) at the price of HK$23.50 per share (the “Placing Price”). J.P. Morgan acted as the placing agent (the “Placing Agent”) for the Placing.

The Placing Price has been fixed at HK$23.50, which represents a discount of approximately 3.49% to the closing price of HK$24.35 per share as quoted on the Stock Exchange on June 22, 2020, being the date of the placing agreement entered into between the Company and the Placing Agent for the Placing. Based on information available in the public domain and to the best knowledge, information and belief of the Company, such discount level represents the lowest among all primary placings of healthcare companies listed in Hong Kong in the last 5 years. The Placing Shares represent (i) approximately 3.80% of the issued share capital of the Company immediately prior to completion of the Placing; and (ii) approximately 3.66% of the enlarged share capital of the Company immediately after completion of the Placing.

The net proceeds from the Placing, after deducting all related costs, commission and expenses, amount to approximately HK$1,541 million. The Company intends to use proceeds from the Placing for repayment of bank loans of the Group, funding potential business development and investments in the future if such opportunities arise and for general working capital of the Group.
MicroPort® Cardiac Rhythm Management Business Announces New Investor

On July 3, 2020, MicroPort Scientific Corporation ("MicroPort") announced that MicroPort Cardiac Rhythm Management Limited ("MicroPort CRM"), its subsidiary focused on developing and commercializing implantable pacemaker and defibrillator devices and related technologies to manage cardiac rhythm disorders, has entered into definitive agreements in connection with its Series B financing with total investment proceeds of US$105 million. GL Ventures, the venture capital arm of Hillhouse Capital Group, will lead the Series B investment and will invest US$50 million. Current MicroPort CRM investor Yunfeng Capital will also participate with an additional investment of US$25 million. MicroPort will also invest USD$30 million through its wholly-owned subsidiary MicroPort International Corp. Limited ("MicroPort International"). Once the transaction is complete, MicroPort International will continue to be the majority shareholder of MicroPort CRM. The financing is expected to close by end of July 2020, subject to customary closing conditions.

Mr. Jonathan Chen, Chief International Business Officer of MicroPort and Chairman of InterContinental CRM Committee said: “The capital injection of external investors in MicroPort CRM combined with other achievements since the acquisition of the CRM business. Such as progressively expanding our product portfolio with key approvals, transitioning to a direct sales model in Japan market, and developing break-through technologies by leveraging our cross-border R&D teams, have laid a solid foundation from which to build a formidable global CRM company. We welcome our new partner Hillhouse Capital and also express gratitude to our existing partner Yunfeng Capital to continue on our journey of building MicroPort CRM into the fastest growing CRM business in the world.”
MicroPort® Assisted Reproductive Technology (ART) Business Announces New Investors

MicroPort Scientific Corporation (“MicroPort®”) announced on July 22 that Shanghai Horizon Medical Technology Co., Ltd. (“MicroPort® Horizon”), a subsidiary focused on the Assisted Reproductive Technology (ART) business, has officially entered into a 130 million yuan (US$19 million) funding agreement with new investors in accordance with its plan. The investment is led by Shenzhen Capital Group Co., Ltd. and the group’s funds. After the completion of the investment, MicroPort® Horizon will have a valuation of 430 million yuan (US$61 million).

Founded in November 2018, MicroPort® Horizon is focused on medical solutions in the field of ART. Its business covers the R&D, manufacturing, marketing, and technical support of products at every step of the ART treatment process, including egg and sperm collection, fertilization, embryo culture, cryopreservation, and embryo transfer. MicroPort® Horizon has already established strong relationships and collaborations with many well-known IVF centers and universities across China.
MicroPort® Attends the 15th Edition of Ice City Conference of Cardiology (ICC 2020)

From June 19 to 21, 2020, Shanghai MicroPort Medical (Group) Co., Ltd. (“MicroPort®”) attended the 15th Edition of Ice City Conference of Cardiology (ICC 2020) which had the theme of “Innovation, Standard and Cooperation” and hosted live cases, satellite conferences and scientific symposiums focused on ten areas including coronary heart disease, cardiac pacing and electrophysiology and structural heart. More than 500 healthcare professionals and scholars from home and abroad were invited to participate in online lecturers and live streaming of operations.

In the symposium on absorbable stents, Professor Bo Xu from Fuwai Hospital of Chinese Academy of Medical Sciences gave a presentation titled “National Product, Clinical Trial Protocol and Progress Interpretation for MicroPort®-developed Firesorb®”. Professor Xu also released part of the trial results. Professor Xu proved the outstanding performance with cases and angiography proofs and gave an introduction of the progress of the ongoing FUTURE-II and FUTURE-III studies. He commented that the Firesorb® stent would be another masterpiece of MicroPort® in the field of vascular intervention, with the device’s data showing high-level clinical potential and wide application prospect.
China Interventional Therapeutics (CIT)
2020 Unveiled: MicroPort® Presents Integrated PCI Solution in the First Phase of CIT 2020

Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort") recently presented its integrated PCI solution including FireCondor™ stent and Firefighter™ balloon in the first phase of China Interventional Therapeutics (CIT) 2020. Due to the COVID-19 pandemic, the CIT 2020 under the theme of “Cooperation, Innovation and Commercialization” was held online from June 17 to November in ten phases with different focuses and specialties to promote scientific exchanges on a more comprehensive basis.

During the first phase of the event, which was held from June 17 to 19, MicroPort co-organized a live case session that was a highlight of the conference. The cases were performed at the new hybrid cath lab commissioned at the Fuwai Hospital which was regarded the world’s best of its likes. The most striking feature of the cath lab was four huge screens that could provide a clearer display of various kinds of images. The cath lab also allowed physicians to perform the procedures requiring different vascular accesses at any positions of the catheter bed. During the live case session, Professor Yida Tang and Jie Qian from Fuwai Hospital opted for the FireCondor™ stent and Firefighter™ balloon. Professor Xinkai Qu from Huadong Hospital Affiliated to Fudan University and other healthcare professionals participated in the discussions on the cases streamed live. The outstanding performance that MicroPort® integrated PCI solution demonstrated in complex lesions was very well received by the healthcare professionals in attendance.
Tibial Resection Alignment System Wins Reddot Award 2020 Best of the Best for Design Concept

The Tibial Resection Alignment System developed by Suzhou MicroPort OrthoRecon Co., Ltd. recently won the Reddot Award 2020 Best of the Best for Design Concept.

The Reddot Award is an international design competition for product design, communication design and design concepts. This year’s edition of the competition has attracted 4,170 entries from 52 countries and regions around the world. The Reddot Award 2020 Best of the Best for Design Concept is the top Reddot Award to honor design concepts.

The Reddot Award can trace back to the “Verein Industrieform” association of Germany and spans more than 60 years. The award has become an internationally recognized award in the field of creative ideas and designs. It is called one of the world’s top three design awards along with the iF Design Award and IDEA Award. It is also established as a wind vane for industrial design trends worldwide.

There are prize categories for product design, brand and communication design as well as design concepts. The Reddot Award 2020 Best of the Best for Design Concept that rates breakthrough designs is the top award in the category for design concepts. The award celebrates the most outstanding design concepts in each segment. Only 42 design concept submissions were honored with the award in 2020.
**MicroPort® Makes the List of Top 60 Companies of 520 Accountability Branding in 2020**

MicroPort Scientific Corporation (“MicroPort®”) was recently recognized as Top 60 Companies of 520 Accountability Branding in 2020 for its continued demonstration of accountability in the field of corporate citizenship and in the national fight against the COVID-19 pandemic. The honor was announced during the 5th edition of China Corporate Citizenship 520 Accountability Branding Summit (2020), which was held online by China Committee of Corporate Citizenship and Tencent Foundation.

In the future, MicroPort® will continue to integrate corporate citizenship into every link of corporate operation and development, so as to achieve the harmonious development of both the company and the society. MicroPort® will behave in an accountable manner to provide an explanation of corporate citizenship in a real-world context, as MicroPort® provides patients worldwide with more high-quality and accessible therapeutic solutions that can save and transform patients’ lives or improve their quality of life.
For more information, please contact:

**Martin Sun**  
Chief Financial Officer  
MicroPort Scientific Corporation  
Tel: (86)(21) 38954600  
Email: ir@microport.com

**Leanne Li**  
Board Secretary & Vice President  
MicroPort Scientific Corporation  
Tel: (86)(21) 38954600  
Email: ir@microport.com